JP7450585B2 - CD66cに特異的に結合する抗体およびその用途 - Google Patents
CD66cに特異的に結合する抗体およびその用途 Download PDFInfo
- Publication number
- JP7450585B2 JP7450585B2 JP2021118114A JP2021118114A JP7450585B2 JP 7450585 B2 JP7450585 B2 JP 7450585B2 JP 2021118114 A JP2021118114 A JP 2021118114A JP 2021118114 A JP2021118114 A JP 2021118114A JP 7450585 B2 JP7450585 B2 JP 7450585B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cells
- cd66c
- cancer
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 title claims description 12
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 title claims 3
- 206010028980 Neoplasm Diseases 0.000 claims description 108
- 239000000427 antigen Substances 0.000 claims description 90
- 108091007433 antigens Proteins 0.000 claims description 90
- 102000036639 antigens Human genes 0.000 claims description 90
- 201000011510 cancer Diseases 0.000 claims description 88
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 82
- 230000027455 binding Effects 0.000 claims description 67
- 239000013598 vector Substances 0.000 claims description 33
- 150000007523 nucleic acids Chemical class 0.000 claims description 32
- 102000039446 nucleic acids Human genes 0.000 claims description 31
- 108020004707 nucleic acids Proteins 0.000 claims description 31
- 239000012634 fragment Substances 0.000 claims description 30
- 206010009944 Colon cancer Diseases 0.000 claims description 24
- 208000029742 colonic neoplasm Diseases 0.000 claims description 22
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 21
- 206010017758 gastric cancer Diseases 0.000 claims description 21
- 239000007787 solid Substances 0.000 claims description 21
- 201000011549 stomach cancer Diseases 0.000 claims description 21
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 206010027476 Metastases Diseases 0.000 claims description 11
- 230000009401 metastasis Effects 0.000 claims description 11
- 206010006187 Breast cancer Diseases 0.000 claims description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims description 10
- 208000014018 liver neoplasm Diseases 0.000 claims description 9
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 7
- 201000005202 lung cancer Diseases 0.000 claims description 7
- 239000003112 inhibitor Substances 0.000 claims description 6
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 description 200
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 59
- 108090000623 proteins and genes Proteins 0.000 description 59
- 230000001093 anti-cancer Effects 0.000 description 51
- 102000004169 proteins and genes Human genes 0.000 description 40
- 210000001744 T-lymphocyte Anatomy 0.000 description 39
- 241000699666 Mus <mouse, genus> Species 0.000 description 34
- 238000000034 method Methods 0.000 description 34
- 238000001727 in vivo Methods 0.000 description 33
- 230000000694 effects Effects 0.000 description 32
- 230000014509 gene expression Effects 0.000 description 32
- 230000001965 increasing effect Effects 0.000 description 28
- 238000003501 co-culture Methods 0.000 description 23
- 238000011579 SCID mouse model Methods 0.000 description 22
- 238000004458 analytical method Methods 0.000 description 21
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 19
- 230000006044 T cell activation Effects 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 19
- 102000008096 B7-H1 Antigen Human genes 0.000 description 18
- 238000010171 animal model Methods 0.000 description 18
- 239000000126 substance Substances 0.000 description 18
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 16
- 230000015861 cell surface binding Effects 0.000 description 16
- 230000004913 activation Effects 0.000 description 15
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 15
- 230000028327 secretion Effects 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 230000009257 reactivity Effects 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 12
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 210000002865 immune cell Anatomy 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 230000002950 deficient Effects 0.000 description 11
- 108010062802 CD66 antigens Proteins 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- 230000002776 aggregation Effects 0.000 description 10
- 238000004220 aggregation Methods 0.000 description 10
- 239000002246 antineoplastic agent Substances 0.000 description 10
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 10
- 101710190842 Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 9
- 230000008859 change Effects 0.000 description 9
- 238000002372 labelling Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000005880 cancer cell killing Effects 0.000 description 8
- 239000013613 expression plasmid Substances 0.000 description 8
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 7
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 108700012359 toxins Proteins 0.000 description 7
- 230000009466 transformation Effects 0.000 description 7
- 206010003445 Ascites Diseases 0.000 description 6
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 6
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 6
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 6
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 6
- -1 Tamra Chemical compound 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 5
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 102000004503 Perforin Human genes 0.000 description 4
- 108010056995 Perforin Proteins 0.000 description 4
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000025164 anoikis Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 229930192851 perforin Natural products 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 238000009007 Diagnostic Kit Methods 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- 238000011789 NOD SCID mouse Methods 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 239000002458 cell surface marker Substances 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 210000004602 germ cell Anatomy 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000004020 luminiscence type Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 2
- 108091023037 Aptamer Proteins 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 239000012830 cancer therapeutic Substances 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000006333 protein structural change Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- CZWUESRDTYLNDE-UHFFFAOYSA-N (2z)-2-[(2e,4e,6e)-7-[1-(5-carboxypentyl)-3,3-dimethyl-5-sulfoindol-1-ium-2-yl]hepta-2,4,6-trienylidene]-1-ethyl-3,3-dimethylindole-5-sulfonate Chemical compound CC1(C)C2=CC(S([O-])(=O)=O)=CC=C2N(CC)\C1=C/C=C/C=C/C=C/C1=[N+](CCCCCC(O)=O)C2=CC=C(S(O)(=O)=O)C=C2C1(C)C CZWUESRDTYLNDE-UHFFFAOYSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- VWLAGVVQCMHHJW-UHFFFAOYSA-N 1-(2-aminoethyl)-3-(3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-yl)thiourea Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(NC(=S)NCCN)=CC=C21 VWLAGVVQCMHHJW-UHFFFAOYSA-N 0.000 description 1
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 1
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- AGJBKFAPBKOEGA-UHFFFAOYSA-M 2-methoxyethylmercury(1+);acetate Chemical compound COCC[Hg]OC(C)=O AGJBKFAPBKOEGA-UHFFFAOYSA-M 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical compound O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- LIZDKDDCWIEQIN-UHFFFAOYSA-N 6-[2-[5-(3-ethyl-1,1-dimethyl-6,8-disulfobenzo[e]indol-2-ylidene)penta-1,3-dienyl]-1,1-dimethyl-6,8-disulfobenzo[e]indol-3-ium-3-yl]hexanoate Chemical compound C1=CC2=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C=C2C(C2(C)C)=C1N(CC)\C2=C\C=C\C=C\C1=[N+](CCCCCC([O-])=O)C2=CC=C(C(=CC(=C3)S(O)(=O)=O)S(O)(=O)=O)C3=C2C1(C)C LIZDKDDCWIEQIN-UHFFFAOYSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- FWEOQOXTVHGIFQ-UHFFFAOYSA-N 8-anilinonaphthalene-1-sulfonic acid Chemical compound C=12C(S(=O)(=O)O)=CC=CC2=CC=CC=1NC1=CC=CC=C1 FWEOQOXTVHGIFQ-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 description 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 230000000970 DNA cross-linking effect Effects 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 229940122029 DNA synthesis inhibitor Drugs 0.000 description 1
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 1
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 1
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101710116782 Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 229940122255 Microtubule inhibitor Drugs 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010084592 Saporins Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 1
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 102000054751 human RUNX1T1 Human genes 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000009562 momordin Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- VELGMVLNORPMAO-JTFNWEOFSA-N n-[(e)-1-[(3r,4r,5s,6r)-5-[(2s,3r,4r,5r,6r)-5-[(2s,3r,4r,5r,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)-4-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydroxy-6-(hydroxym Chemical compound O[C@@H]1[C@@H](O)C(OCC(NC(=O)CCCCCCCCCCCCCCCCC)C(O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 VELGMVLNORPMAO-JTFNWEOFSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 229940124788 therapeutic inhibitor Drugs 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
蛍光値変異率=(高温条件で測定した蛍光値-低温条件で測定した蛍光値)/(低温条件で測定した蛍光値)
1.1.抗-CD66c抗体遺伝子配列クローニング
8F5抗体遺伝子はMouse Ig-Primer Set(Millipore、Cat.#:69831)を用いてクローニングした。8F5ハイブリドーマから分離したRNAからMouse Ig-Primer Setを用いてPCRを行い、これをpGem-Tベクター(Promega、Cat.#:A3600)に挿入した後、シークエンシングを通じてDNA塩基配列を確認し、IMGT site(www.imgt.org)を通じてマウス抗体遺伝子を確認した。分析された8F5抗体重鎖および軽鎖可変領域配列は以下の通りである。
前記製作された抗-CD66cマウス抗体8F5のアミノ酸配列に基づいて、抗-CD66cキメラ抗体を製作した。
抗-CD66cキメラ抗体の発現のために、重鎖発現用プラスミドと軽鎖発現用プラスミドをそれぞれ製作した。軽鎖発現用プラスミドはpOptiVEC(Invitrogen社)ベクターを使用し、重鎖発現用プラスミドはpcDNA3.3(Invitrogen社)ベクターを使用した。
前記製作されたpcDNA3.3-anti-CD66c重鎖発現プラスミドとpOptiVEC-anti-CD66c軽鎖発現プラスミドをCHO細胞由来のDG44細胞(Invitrogen)にトランスフェクション(transfection)させ形質転換過程を行った。
2.1 In silico Humanizationによる組換え抗体配列選定 マウスCD66c抗体、8F5(重鎖アミノ酸配列:7 重鎖コーディングDNA:SEQ ID NO:62;軽鎖アミノ酸配列:SEQ ID NO:8;軽鎖コーディングDNA:SEQ ID NO:63)の重鎖、軽鎖それぞれのCDR部位配列(CDRH1:ASGYSFTDYTMN)SEQ ID NO:1、CDRH2:SEQ ID NO:2(LINPFHGGTVSNQRFKV);CDRH3:SEQ ID NO:3(VRGDPVRHYYALAY);CDRL1:SEQ ID NO:4(GASENVYGTL);CDRL2:SEQ ID NO:5(GATNLAD);CDRL3:SEQ ID NO:6(VATYYCQNVLSAPYT)をできるだけ類似するように維持して抗原結合力が同等であるか優れていれば、ヒト抗体遺伝子をコーディングしている生殖細胞系列(germline)の配列を基盤にしてフレームワーク領域(Framework region)に対する部位配列を組換えたヒト化抗体配列をin silico方法で選別した。マウスCD66c抗体8F5の重鎖、軽鎖それぞれ配列と最も類似性が高くてヒト化組換え抗体配列の主鎖(backbone)として使用したヒト抗体生殖細胞系列(Germline)遺伝子は下記表5の通りである。前記マウスCD66c抗体の重鎖可変領域と軽鎖可変領域のアミノ酸配列と核酸配列、そして重鎖可変領域と軽鎖可変領域のCDR配列を下記表6に示す。
選別された抗体配列はそれぞれヒトIgG1重鎖不変領域とカッパ(kappa)軽鎖不変領域と連結してヒトIgG1形態に293細胞で発現させた。トランスフェクション(Transfection)した後、7日後に培養液はKanCap A resin(Kaneca社)を用いてヒト化組換え抗体を精製した。
2-3-1 細胞結合分析
発現させた96種のヒト化組換え抗体をそれぞれ同量(1ug)をCD66c陽性細胞であるA549非小細胞肺癌細胞株が入っている試験管に入れて4℃で30分間反応させた後にPBSで水洗し、FITC-conjugated goat anti-Human IgG(ダイノナ株式会社(DiNona Inc)、Korea)を入れて4℃で15分間培養した。再びPBSで水洗した後、フローサイトメーター(Stratedigm、S1000EXi)で分析してその結果を下記に記載した。
前記のように選定した8種ヒト化組換え抗体の中から、キメラ抗体に比べて細胞結合力を基準にして高い結合力を示す5種類のヒト化組換え抗体を選択し、これらをELISA方法でCD66c抗原および類似CD66抗原に対する結合力分析を実施した。
前記抗原および細胞結合様相を通じて選定した、前記実施例3.3の5種のヒト化組換え抗体を高い温度条件に放置して抗体の安定性の有無を分析する実験を行った。
蛍光値変異率=(高温条件で測定した蛍光値-低温条件で測定した蛍光値)/(低温条件で測定した蛍光値)
前記実施例2.3で選定された5種のヒト化組換え抗体を実際大部分の治療用抗体を発現させるために使用するCHO細胞に発現させて分析した。選定された5種のヒト化組換え抗体を構成するための軽鎖および重鎖可変領域DNA配列をコドン最適化過程を経た後、合成してヒトIgG1不変領域遺伝子とoverlay PCR方法で連結してXhoIとEcoRI遺伝子切片でpcDNA3.4ベクター(Life Technology社)にクローニングした。前記表11は、CHO細胞発現のために選別されたヒト化抗体の軽鎖および重鎖組み合わせを示す。
3.1.CD8+T細胞と癌細胞LS174Tの共同培養に続くT細胞活性サイトカイン分析および癌細胞の生存率(viability)分析
CD8+T細胞はヒト血液細胞からMagniSort(registered trademark)Human CD8 T cell Enrichment Kit(Ebioscience、cat.#:8804-6812-74)を用いて分離した。6ウェルプレートの各ウェルにCD8+T細胞は1×106個の細胞を、大腸癌癌細胞であるLS174Tは2×105個の細胞を同時に入れて、ウェル当り2mlの量(volume)になるように10%FBS/RPMI培地にして培養した。この時、キメラ8F5抗体は20ug/mlになるように処理した。培養後、3日と5日目に培養液を各100ulずつ取って培養液のIFNγとパーフォリン(perforin)分泌量をHuman CD8+ T-Cell Magnetic Bead Panel(Millipore、Cat.#:HCD8MAG-15K)キットを用いて測定した。培養7日目に大腸癌細胞LS174Tを分離して7-AADで染色後、フローサイトメーター(Flow cytometer)で細胞の生存率(viability)を測定した。図7aは大腸癌細胞株であるLS174T細胞とヒトCD8+T細胞を共同培養した条件でキメラ8F5抗体を処理した時、CD8+T細胞が活性化されてIFNγとパーフォリン(perforin)を分泌させる結果であり、図7bは図7aと同一の条件で大腸癌細胞LS174Tがキメラ8F5抗体処理時、細胞死滅が増加するのを示す結果である。
実施例3.1のようにCD8+T細胞を分離して、多様な癌細胞と共同培養条件でキメラ8F5抗体によるT細胞活性をELISOT方法で確認した。Human IFNgamma ELISPOT Ready-SET-Go!(Ebioscience;Cat.#:88-7386-21)キットを用いてIFNγを分析した。各ウェル当り100ulの体積(volume)でCD8+T細胞は2.5×104、癌細胞は5×103細胞を共に入れて3日間培養後、キットで提示する方法でIFNγ分泌する細胞spotsを検出した。
癌細胞とCD8+T細胞の共同培養時、8F5抗体によるT細胞活性が実際8F5抗体の抗原であるCD66c抗原によるものか確認するために、ヒトPBMCを分離してOKT3抗体によるT細胞活性がCD66c抗原によって抑制できるか確認した。
5.1.T細胞活性化の増加
OKT3抗体によるT細胞の活性化をキメラ8F5抗体がどんな影響を与えるか確認するために、0.3mg/ml濃度でOKT3抗体を付着させた35-mmdish条件でヒトPBMCを2×106細胞を入れて3日間培養した。この時、キメラ8F5抗体は20ug/mlになるように処理し、3日後、CD4+T細胞とCD8+T細胞をAnti-Human CD69 PE(Ebioscience、Cat.#:12-0699-41)、Anti-Human CD107a(LAMP-1)PE(Ebioscience、Cat.#:12-1079-41)、Anti-Human CD25 APC(Ebioscience、Cat.#:17-0259-41)で染色した。Anti-CD4-APCおよびAnti-CD8-FITCはダイノナで製造した試薬で染色して各CD4およびCD8グループをフローサイトメーター(Flow cytometer)上でゲーティング(gating)して分析した。図10aおよび図10bは付着されたOKT3抗体によるT細胞活性化条件でキメラ8F5抗体が活性化を増加させてCD69、CD107、CD25などの様々な活性化細胞表面マーカ蛋白質を増加させるのを示す結果である。
キメラ8F5抗体処理によるT細胞活性化を追加的に確認するためにMLR(Mixed Lymphocyte Reaction)実験を行った。まず、ヒトPBMCを分離して培養皿に付着された細胞のみIL-4(5×103unit/ml、JWCreagene)とGM-CSF(5×103unit/ml、JWCreagene)を3日間隔で二回処理して樹状細胞(Dendritic cell)に分化させた。その後、他のヒトのPBMCと共にPBMC:DC比率が5:1になるように混合して5日間培養した。PBMC細胞数は、12ウェルプレートの場合、ウェル当り1.4×106細胞を使用した。5日後、細胞は分離してCD4-FITC/CD107-PE/CD25-APCまたはCD8-FITC/CD107-PE/CD25-APCで染色してフローサイトメーター(Flow cytometer)分析を行った。図11aおよび図11bは互いに異なるヒトの樹状細胞とPBMCを混合するMLR(Mixed Lymphocytes Reaction)条件でキメラ8F5抗体がCD4、CD8陽性細胞を活性化させるのを示す結果である。
胃癌患者とPBMC共同培養時キメラ8F5抗体によるPBMC活性化を評価しようとした。実験室で培養している癌細胞でない実際胃癌患者の腹水から癌細胞を分離して、キメラ8F5抗体投与時免疫細胞活性化されるかどうかを確認した。胃癌患者の腹水サンプルはソウル峨山病院で獲得し、腹水サンプルからCD66c陽性が確認されたサンプルの胃癌細胞と同一患者の血液からPBMCを分離して実施例3.2のようにELISPOT試験を行った。
癌細胞とPBMC共同培養時キメラ8F5抗体によってPD-L1発現量増加を評価しようとした。癌細胞LS-174-T(大腸癌細胞株)、NCI-N87(胃癌細胞株)A549(非小細胞肺癌細胞株)とPBMC共同培養時、キメラ8F5抗体による免疫チェックポイント関連蛋白質の変化を確認するためにPD-L1の細胞表面変化を観察した。6ウェルプレート上で各ウェル当り癌細胞:PBMC=1:3の比率で(0.5×106cells:1.5×106cells)混合して24時間培養し、この時、抗体は20ug/mlで処理した。癌細胞およびPBMC細胞表面のPD-L1はAnti-Human CD274(PD-L1、B7-H1)PE(Ebioscience、Cat.#:12-5983-41)で染色し、癌細胞とPBMCを区分するためにCD45-FITC(ダイノナ)を同時染色した。
癌細胞とPBMC共同培養時ヒト化8F5抗体によるPBMC活性化を評価しようとした。即ち、表11のように選定されたヒト化8F5抗体の中から5種類を選定して、実施例3.2のようにELISPOT試験を行った。同時培養した癌細胞はA549非小細胞癌細胞株(lung adenocarcinoma細胞株)を使用し、投与した抗体の濃度は20ug/mlである。3日後、IFNγ陽性spotを確認した時、図14のように試験した5種類全てのヒト化8F5抗体がキメラ8F5抗体と同様な水準でIFNγ陽性spotを増加させたことが分かり、一部はキメラ8F5抗体よりさらに多くの程度の増加傾向を示した。したがって、機能的にヒト化8F5抗体はキメラ8F5抗体と非常に類似しているのを確認することができた。
9-1:癌細胞とCD3+T細胞の共同培養
癌細胞とCD3陽性T細胞との共同培養時ヒト化8F5抗体による癌細胞の死滅化を評価しようとした。大腸癌細胞株(Colon cancer cell line)であるLS-174-T細胞とヒトのCD3陽性T細胞を共同培養する条件で抗体処理時、活性化されたT細胞によって癌細胞が死滅するかをin vitro上で確認した。
癌細胞とPBMC共同培養時ヒト化8F5(protein ID:3019)抗体による癌細胞の死滅化を評価しようとした。
10-1:NOD/SCIDマウスモデルを用いたキメラ8F5抗体の抗癌効能評価 キメラ8F5抗体のIn vivo免疫抗癌効果を確認するために、免疫欠乏マウスであるNOD/SCIDマウスを用いた。従来の先行特許(大韓民国:10-1214177;米国:8404812)ではNudeマウスを用いて抗癌効果を示したが、Nudeマウスを用いた動物実験セットは抗癌効果を示す免疫細胞がヒト由来でないマウス免疫細胞を効能細胞として用いたものであって、実際ヒトで候補抗体が治療的効能を示すことができるのを立証するのに限界がある。したがって、実質的なヒト免疫細胞による動物実験内癌細胞死滅に対する抗体の抗癌効果を評価するために、マウスT細胞をはじめとする免疫細胞が欠乏されているNOD/SCIDマウスを動物実験に使用した。
実施例10-1と実質的に同一の方法で動物モデルを用いた抗癌効能を評価したが、但し、大腸癌細胞であるLS-174-T細胞を用いたNOD-SCIDマウス移植モデルとヒト化8F5抗体(protein ID:3019、表11)を使用し、実験結果を図16cに示した。
実施例10-1と10-2で使用したNOD/SCIDマウスより免疫欠乏程度がさらに深刻なNSGマウスを用いた動物実験を行った。NSGマウスはNOD/SCIDマウスでIL2レセプターガンマ(IL2Rγ)遺伝子に突然変異を誘導してNOD/SCIDマウスに残留するNK細胞の活性を完全に除去したマウスであって、これは微量残留するマウス免疫細胞による影響を完全に除去してひたすら一由来免疫細胞による影響を評価するためである。
Claims (9)
- (i)配列番号18のアミノ酸配列を含む重鎖可変領域および配列番号21のアミノ酸配列を含む軽鎖可変領域、または、
(ii)配列番号17のアミノ酸配列を含む重鎖可変領域および配列番号20のアミノ酸配列を含む軽鎖可変領域を含む、抗-CD66c抗体またはその抗原結合断片。 - 前記抗原結合断片は、前記抗-CD66c抗体のscFv、(scFv)2、Fab、Fab’またはF(ab’)2である、請求項1に記載の抗-CD66c抗体またはその抗原結合断片。
- 請求項1に記載の抗-CD66c抗体またはその抗原結合断片を含む、癌および癌転移から選択された疾病の予防または治療のための薬学組成物。
- 前記癌は、CD66c陽性の固形癌である、請求項3に記載の薬学組成物。
- 前記固形癌は、CD66c陽性の肺癌、大腸癌、胃癌、肝癌、乳癌、または前立腺癌である、請求項4に記載の薬学組成物。
- PD-1またはPD-L1結合抑制剤をさらに含む、請求項3に記載の薬学組成物。
- 請求項1に記載の抗体またはその抗原結合断片をコードする、核酸。
- 請求項7に記載の核酸を含む、組換えベクター。
- 請求項8に記載の組換えベクターを含む、組換え細胞。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2016-0151359 | 2016-11-14 | ||
KR20160151359 | 2016-11-14 | ||
JP2019547056A JP2019535319A (ja) | 2016-11-14 | 2017-11-14 | CD66cに特異的に結合する抗体およびその用途 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019547056A Division JP2019535319A (ja) | 2016-11-14 | 2017-11-14 | CD66cに特異的に結合する抗体およびその用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021177770A JP2021177770A (ja) | 2021-11-18 |
JP7450585B2 true JP7450585B2 (ja) | 2024-03-15 |
Family
ID=62110206
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019547056A Pending JP2019535319A (ja) | 2016-11-14 | 2017-11-14 | CD66cに特異的に結合する抗体およびその用途 |
JP2021118114A Active JP7450585B2 (ja) | 2016-11-14 | 2021-07-16 | CD66cに特異的に結合する抗体およびその用途 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019547056A Pending JP2019535319A (ja) | 2016-11-14 | 2017-11-14 | CD66cに特異的に結合する抗体およびその用途 |
Country Status (13)
Country | Link |
---|---|
US (1) | US11220543B2 (ja) |
EP (1) | EP3560957A4 (ja) |
JP (2) | JP2019535319A (ja) |
KR (1) | KR102019032B1 (ja) |
CN (1) | CN110382533B (ja) |
AU (1) | AU2017358359B2 (ja) |
BR (1) | BR112019009771A2 (ja) |
CA (1) | CA3043691C (ja) |
IL (1) | IL266516B (ja) |
MX (1) | MX2019005491A (ja) |
PH (1) | PH12019501050A1 (ja) |
SG (1) | SG11201903800XA (ja) |
WO (1) | WO2018088877A2 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3628688A1 (en) | 2015-03-23 | 2020-04-01 | Bayer Pharma Aktiengesellschaft | Anti-ceacam6 antibodies and uses thereof |
WO2019221574A1 (ko) * | 2018-05-14 | 2019-11-21 | 다이노나(주) | 골수유래억제세포 관련 질환의 예방 및 치료 용도 |
KR102373502B1 (ko) * | 2018-05-14 | 2022-03-11 | 주식회사 금호에이치티 | 골수유래억제세포 관련 질환의 예방 및 치료 용도 |
SG11202105078XA (en) * | 2018-11-14 | 2021-06-29 | Bayer Ag | Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer |
KR102027248B1 (ko) * | 2018-12-14 | 2019-10-01 | 건양대학교 산학협력단 | 유방암 줄기세포 검출용 바이오마커 및 이의 용도 |
CN112521509B (zh) * | 2020-12-23 | 2022-07-08 | 姚雪英 | 一种抗ceacam5人源化抗体、其缀合物及其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009106280A (ja) | 2007-10-19 | 2009-05-21 | Centocor Inc | ヒトに適合したモノクローナル抗体における使用法 |
US20110212095A1 (en) | 2010-02-26 | 2011-09-01 | Dinona Inc. | Epitope of cd66c specific to lung adenocarcinoma and antibody recognizing the same |
JP2015518826A (ja) | 2012-05-15 | 2015-07-06 | ブリストル−マイヤーズ スクイブ カンパニーBrist | Pd−1/pd−l1シグナル伝達を破壊することによる癌免疫療法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005102456A1 (en) | 2004-03-27 | 2005-11-03 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Composition and method for cancer treatment |
US8883162B2 (en) * | 2005-10-19 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
KR101214177B1 (ko) | 2010-02-26 | 2012-12-21 | 다이노나(주) | CD66c의 폐선암 특이적 에피토프 및 이를 인식하는 항체 |
AR084141A1 (es) * | 2010-11-19 | 2013-04-24 | Imai Toshio | Anticuerpos neutralizadores anti-ccl20 |
US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
ES2808684T3 (es) * | 2013-11-25 | 2021-03-01 | Famewave Ltd | Composiciones que incluyen anticuerpos anti-ceacam1 y anti-pd para terapia de cáncer |
KR101710936B1 (ko) | 2014-09-12 | 2017-02-28 | 전영권 | 태양전지 및 그 제조방법 |
EP3628688A1 (en) * | 2015-03-23 | 2020-04-01 | Bayer Pharma Aktiengesellschaft | Anti-ceacam6 antibodies and uses thereof |
KR101783907B1 (ko) * | 2016-03-15 | 2017-10-10 | 다이노나(주) | CD66c에 대한 항체와 화학치료제를 포함하는 폐암 예방 또는 치료용 약학조성물 |
WO2017209318A1 (ko) | 2016-05-30 | 2017-12-07 | 다이노나(주) | 탄산탈수소화 효소에 결합하는 항체 및 이의 용도 |
-
2017
- 2017-11-14 JP JP2019547056A patent/JP2019535319A/ja active Pending
- 2017-11-14 US US16/346,259 patent/US11220543B2/en active Active
- 2017-11-14 KR KR1020170151602A patent/KR102019032B1/ko active IP Right Grant
- 2017-11-14 CA CA3043691A patent/CA3043691C/en active Active
- 2017-11-14 MX MX2019005491A patent/MX2019005491A/es unknown
- 2017-11-14 AU AU2017358359A patent/AU2017358359B2/en active Active
- 2017-11-14 EP EP17869760.3A patent/EP3560957A4/en active Pending
- 2017-11-14 WO PCT/KR2017/012891 patent/WO2018088877A2/ko active Application Filing
- 2017-11-14 BR BR112019009771A patent/BR112019009771A2/pt unknown
- 2017-11-14 CN CN201780070516.5A patent/CN110382533B/zh active Active
- 2017-11-14 SG SG11201903800XA patent/SG11201903800XA/en unknown
-
2019
- 2019-05-07 IL IL266516A patent/IL266516B/en unknown
- 2019-05-10 PH PH12019501050A patent/PH12019501050A1/en unknown
-
2021
- 2021-07-16 JP JP2021118114A patent/JP7450585B2/ja active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009106280A (ja) | 2007-10-19 | 2009-05-21 | Centocor Inc | ヒトに適合したモノクローナル抗体における使用法 |
US20110212095A1 (en) | 2010-02-26 | 2011-09-01 | Dinona Inc. | Epitope of cd66c specific to lung adenocarcinoma and antibody recognizing the same |
JP2015518826A (ja) | 2012-05-15 | 2015-07-06 | ブリストル−マイヤーズ スクイブ カンパニーBrist | Pd−1/pd−l1シグナル伝達を破壊することによる癌免疫療法 |
Non-Patent Citations (2)
Title |
---|
Acta Biochim Biophys Sin (2014) Vol.46, pp.283-290 |
Cancer Res (2005) Vol.65, No.19, pp.8809-8817 |
Also Published As
Publication number | Publication date |
---|---|
EP3560957A2 (en) | 2019-10-30 |
JP2021177770A (ja) | 2021-11-18 |
IL266516B (en) | 2021-12-01 |
AU2017358359B2 (en) | 2021-04-01 |
BR112019009771A2 (pt) | 2019-09-17 |
AU2017358359A1 (en) | 2019-05-30 |
KR20180054492A (ko) | 2018-05-24 |
WO2018088877A3 (ko) | 2018-10-04 |
MX2019005491A (es) | 2019-08-12 |
IL266516A (en) | 2019-08-29 |
WO2018088877A9 (ko) | 2018-11-08 |
KR102019032B1 (ko) | 2019-09-06 |
WO2018088877A2 (ko) | 2018-05-17 |
PH12019501050A1 (en) | 2019-12-11 |
SG11201903800XA (en) | 2019-05-30 |
CN110382533A (zh) | 2019-10-25 |
EP3560957A4 (en) | 2020-10-21 |
CA3043691A1 (en) | 2018-05-17 |
JP2019535319A (ja) | 2019-12-12 |
US11220543B2 (en) | 2022-01-11 |
CN110382533B (zh) | 2023-09-22 |
CA3043691C (en) | 2022-11-29 |
US20190263905A1 (en) | 2019-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7450585B2 (ja) | CD66cに特異的に結合する抗体およびその用途 | |
US9388248B2 (en) | Anti-CXCR4 antibodies and their use for the treatment of cancer | |
EP3604338A1 (en) | Anti-ox40 antibody and use thereof | |
US9249223B2 (en) | Humanized anti CXCR4 antibodies for the treatment of cancer | |
JP2022516505A (ja) | 癌および他の疾患の治療のための、クローディン18.2に特異的な結合分子、その組成物および方法 | |
JP2021129585A (ja) | 炭酸脱水素酵素に結合する抗体およびその用途 | |
JP2020125352A (ja) | 抗−cd43抗体およびその癌治療用途 | |
JP7165855B2 (ja) | 骨髄由来抑制細胞関連疾患の予防および治療用途 | |
KR101917098B1 (ko) | 탄산탈수소화 효소에 결합하는 항체 및 이의 용도 | |
EP3619237B1 (en) | Antibodies against carcinoembryonic antigen for cancer therapy and diagnosis | |
TW202342528A (zh) | 抗人類cxcl1抗體 | |
WO2019221574A1 (ko) | 골수유래억제세포 관련 질환의 예방 및 치료 용도 | |
CN114907478A (zh) | 结合lag-3的抗体及其用途 | |
CN115403670A (zh) | 抗cd40抗体及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210813 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210813 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210909 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220819 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20220930 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220930 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221121 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230203 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230703 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230818 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231218 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20231221 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240209 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240305 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7450585 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |